Open Label Study of the Safety and Contraceptive Efficacy of BufferGel® With Diaphragm

PHASE2/PHASE3CompletedINTERVENTIONAL

Enrollment

200

Participants

Timeline

Start Date

January 31, 2004

Study Completion Date

May 31, 2006

Conditions

Contraception

Interventions

DRUG

Drug: BufferGel® with diaphragm

Sponsors

Collaborators (1)

All Listed Sponsors

collaborator

Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)

NIH

collaborator

Premier Research

OTHER

lead

ReProtect Inc

INDUSTRY

NCT00397670 - Open Label Study of the Safety and Contraceptive Efficacy of BufferGel® With Diaphragm | Biotech Hunter | Biotech Hunter